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Abstract
Background: Arsenic in groundwater and its accumulation in plants and animals have assumed a
menacing proportion in a large part of West Bengal, India and adjoining areas of Bangladesh.
Because of the tremendous magnitude of the problem, there seems to be no way to tackle the
problem overnight. Efforts to provide arsenic free water to the millions of people living in these
dreaded zones are being made, but are awfully inadequate. In our quest for finding out an easy, safe
and affordable means to combat this problem, a homeopathic drug, Arsenicum Album-30, appears
to yield promising results in mice. The relative efficacies of two micro doses of this drug, namely,
Arsenicum Album-30 and Arsenicum Album-200, in combating arsenic toxicity have been
determined in the present study on the basis of some accepted biochemical protocols.
Methods: Mice were divided into different sets of control (both positive and negative) and treated
series (As-intoxicated, As-intoxicated plus drug-fed). Alanine amino transferase (ALT) and
aspartate amino transferase (AST) activities and reduced glutathione (GSH) level in liver and blood
were analyzed in the different series of mice at six different fixation intervals.
Results:  Both Arsenicum Album-30 and Arsenicum Album-200 ameliorated arsenic-induced
toxicity to a considerable extent as compared to various controls.
Conclusions: The results lend further support to our earlier views that microdoses of potentized
Arsenicum Album are capable of combating arsenic intoxication in mice, and thus are strong
candidates for possible use in human subjects in arsenic contaminated areas under medical
supervision.
Background
Arsenic contamination has assumed an alarming propor-
tion in some 9 districts of West Bengal, India, so much so
that it has been earmarked as "the biggest arsenic calamity
in the world" [1,2]. In view of rapid spread of various dis-
eases arising out of arsenic contamination (e.g. arsenical
dermatosis, melanosis, keratosis, oedema, gangrin etc.) in
different areas of West Bengal and also in adjoining areas
of Bangladesh [1–4], some effort has been made to pro-
vide arsenic-free drinking water (purified through chemi-
cal plants) to people living in the arsenic-contaminated
zones, but this has proved to be grossly inadequate so far.
From the vastness of the problem and new reports of
arsenic contamination still emerging from other parts of
South East Asia [5–7], Slovakia [8], Mexico [9] etc., a dis-
astrous situation seems to loom large unless a tremendous
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all-out effort is urgently made to bring the situation under
control. The problem became more complex because of
the poor health and hygiene conditions and the relatively
low affordability of the greater majority of population liv-
ing in these zones. and for the lack of awareness of the
possible consequences of arsenic intoxication in most of
them. Mainly with such a background, our initial aim was
to find out suitable antagonists of arsenic poisoning,
which should be i) easy to administer, ii) effective in low
doses, iii) inexpensive and iv) without any toxic effects of
their own. In course of our search, a potentized homeo-
pathic drug, Arsenicum Album-30, was indeed found that
showed highly promising results in combating arsenic
intoxication in mice, in regard to a series of accepted sci-
entific protocols used, such as cytogenetical, histopatho-
logical and biochemical [10–16]. Encouraged by the
positive results obtained in these studies, and also of oth-
ers [17], changes in activities of certain toxicity marker
enzymes like alanine amino transferase (ALT, EC.2.6.1.2,
also known as glutamate pyruvate aminotransferase) and
aspartate amino transferase (AST, EC 2.6.1.1, also known
as glutamate oxaloacetate aminotransferase) and changes
in the level of reduced glutathione (GSH) in liver and
blood tissues of mice, if any, have now been determined
at different periods after single injection of arsenic triox-
ide. The present investigation also aims at ascertaining if
oral administration of either of two micro doses of the
homeopathic drug, Arsenicum Album, namely, Arseni-
cum Album-30 (henceforth to be called Ars Alb-30) and
Arsenicum Album-200 (henceforth to be called Ars Alb-
200) can ameliorate arsenic toxicity by bringing about
positive modulations of these toxicity denoting
parameters.
Materials and methods
Materials
Inbred lines of Swiss albino mice, reared in the animal
house of the Department of Zoology (under supervision
of the Animal Welfare Committee), Kalyani University,
West Bengal, India served as the materials of the present
study. Healthy mice, about 3 to 4 months old, and weigh-
ing between 20 and 25 gm, were used.
Methods
Arsenic intoxication
Mice were intoxicated only with a single dose of 0.1%
As2O3 solution @ 1 ml/100 gm body weight by intraperi-
tonial injection (on day 0). A group of such Arsenic intox-
icated mice were subsequently fed (post-fed) either
potency of the homeopathic drug, Ars Alb-30 or Ars Alb-
200 (two commonly available and frequently used poten-
cies in India), every day till sacrificed as stated below.
Preparation of the drugs
Two potencies of the homoeopathic drug Arsenicum
Album, namely, Ars Alb-30 and Ars Alb-200, respectively,
were prepared as per homoeopathic procedure of dilution
and potentization by Hahnemann Publishing Company
(Hapco), 165, Bepin Behari Ganguly street, Calcutta, from
where it was procured. As per the standard procedure indi-
cated in the Homoeopathic Pharmacopoeia of India, Vol.
I, 1 ml of original metallic salt solution (Mother tincture
prepared from A. R. quality Arsenic trioxide (powder)
completely dissolved in a mixture of glycerine, H.P.I/I.P.,
strong alcohol, H.P.I. and purified water, H.P.I. the
required amount of alcohol) is diluted with 99 ml of rec-
tified spirit (90% ethyl alcohol approx.) and given 10
machine operated, moderate, equal and successive jerks
(i.e. "succussions" through the standard procedure prac-
ticed for preparation of homeopathic potencies by
Hapco) to produce the potency-1. Similarly 1 ml of the
drug solution at potency-1 is again added with 99 ml of
90% ethanol and 10 jerks given to produce potency-2 and
in this way by successive potentization, the 30th and 200th
potencies of Arsenicum Album (Ars Alb-30 and Ars Alb-
200, respectively) were produced (centesimal dilution).
Similarly, alcohol-30 (A-30) and alcohol-200 (A-200)
were potentized from rectified spirit (approx. 90% ethyl
alcohol) by successive jerks and dilution procedure. 1 ml
each of Ars Alb-30, Ars Alb-200, A-30 and A-200 were
finally diluted separately with 20 ml of double distilled
water to make the stock solution of Ars Alb-30, Ars Alb-
200, A-30 and A-200, respectively.
Dose and feeding procedure of drug
Each mouse, either normal or arsenic intoxicated, was
orally fed with the aid of a fine pipette, 1 drop (0.06 ml)
of stock solution of either A-30 (alcohol treated positive
control 1) or of Ars Alb-30 (active drug treatment 1) or of
either A-200 (positive control 2) or Ars Alb-200 (active
drug treatment 2), as the case may be, at a time. The drug
or alcohol feeding was made as follows: 2 hr after injec-
tion of As2O3 and thereafter 2 hourly, a total of 4 times on
the day of injection (only during day time starting from
day 0) followed by thrice daily (six hourly; at 6 a.m., 12
noon and 6 p.m.) on subsequent days till they were sacri-
ficed for analysis of enzymes and reduced glutathione
content at longer intervals.
Experimental design
For each individual group under treatment and control
series, 5 mice were used for each fixation time (i.e. at 24
h, 48 h, 72 h, 7 d, 15 d and 30 d). The fixation times were
selected from our previous experiences on the effects of
Arsenic trioxide in time-course studies carried out in mice
by taking into consideration various cytogenetical
(namely, chromosome aberrations, micronuclei and
other nuclear anomalies, sperm head anomalies etc.) andBMC Complementary and Alternative Medicine 2003, 3 http://www.biomedcentral.com/1472-6882/3/7
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biochemical parameters (namely, protein profiles, acid
and alkaline phosphatases, lipid peroxidases, DNA and
RNA contents, etc) other than the present ones.
The observations were cross-checked as per the blind
checking method (observer not permitted to know if the
sample was from drug fed or un-fed mice) from indexed
cuvettes later deciphered to avoid possibility of bias in
scoring data. Indexing of samples was done by one who
was not within the team of observers.
Treatment series
As2O3 treated groups (As-treated)
This group of mice were injected intra-peritonially with a
single dose of 0.1% As2O3 solution @ 1 ml/100 gm body
weight.
As2O3 treated drug fed groups (As+Ars Alb-30 and As+Ars Alb-200)
This group of arsenic intoxicated mice were post fed with
either of the potentized homeopathic drugs – Ars Alb-30
or Ars Alb-200 at the above mentioned dose and time till
sacrificed.
Control series
Positive control
As2O3 treated alcohol fed groups (As+A-30 and As+A-200)
This group of arsenic intoxicated mice were post fed either
with A-30 or A-200 at the corresponding time and dose till
sacrificed (positive controls for drug-treated series as the
'vehicle' of the drug was ethyl alcohol). At an average a
mouse consumed between a total of 0.003 ml (twice daily
group) to 0.006 ml (4 times a day) of ethyl alcohol (90%)
diluted in distilled water everyday.
Alcohol fed groups (A-30 and A-200)
Normal untreated mice were fed with either alcohol-30
(A-30) or alcohol-200 (A-200) at all the corresponding
intervals as that of the other drug-treated series. This series
was maintained for examining if the feeding of only suc-
cussed alcohol brings forth any modulations of enzyme
activities.
Drug fed groups (Ars Alb-30 and Ars Alb-200)
Normal healthy untreated mice were orally administered
with either of the potentized homeopathic drug, Ars Alb-
30 or Ars Alb-200 at the same dose and frequency as that
of the As-intoxicated plus Ars Alb-30 or Ars Alb-200 fed
mice. These groups were maintained to examine if the
feeding of the drug alone could bring forth certain
changes in their enzymatic activities.
Negative control
Distilled water injected control groups (Dw-control)
This group of normal mice were injected with double dis-
tilled water @ 1 ml/100 gm body weight. This group
served as the negative control for arsenic intoxicated
group as arsenic was dissolved in water.
Untreated normal control group
This normal group of mice were maintained along with
the other treated groups, and not injected with anything.
But as there was practically no difference between Dw
injected and normal untreated control, data of only Dw-
injected series have been provided.
Experimental parameters
Assay of two enzyme protocols, viz., determination of AST
and ALT activity and estimation of the level of an effective
toxicity marker compound, glutathione, in reduced form
(GSH), were made.
Assay of mean activities of alanine amino transferase (ALT) and 
aspartate amino transferase (AST)
For assay of ALT and AST the methods of Bergmeyer and
Brent [18] was followed with some minor modifications.
For the analysis of ALT, 0.1 ml of tissue homogenate was
made to react with 0.5 ml of the substrate solution (L-
alanine) and incubated for 30 minutes at 37°C. This was
followed by addition of 0.5 ml of dintrophenolhydrazine
(DNPH) and then by 5.0 ml 0.4 N NaOH. The absorbance
was measured at 510 nm.
The enzyme activity was determined from the standard
curve drawn using sodium pyruvate as standard solution.
The enzyme activity was expressed as micromol of pyru-
vate formed per minute/mg protein (determined by the
method of Lowry et al [19]).
For AST 0.1 ml of tissue homogenate was made to react
with 0.5 ml of the substrate solution L-asparate and was
incubated for 60 minutes at 37°C. The absorbance was
measured at 510 nm.
Determination of reduced glutathione (GSH) concentration
The reduced glutathione level was determined by the
method of Ellman [20].
0.02 ml of the sample was added to 9 ml of distilled water.
Then 1 ml of phosphate buffer (pH 8.00) was added. 0.02
ml of reagent [Dithiobis(2-nitrobenzoic acid)] was added
to 3 ml of this solution. The absorbance was determined
at 420 nm against blank, where the reagent had not been
added. The concentration of GSH was expressed as nmole
(SH) per unit tissue.
Statsitical analysis
The levels of significance of the data were determined by
Student's t-test by comparing the data of different treated
and their individual and respective control series, i.e.
between any two series, e.g. between drug fed and Dw-fedBMC Complementary and Alternative Medicine 2003, 3 http://www.biomedcentral.com/1472-6882/3/7
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series, or between drug-fed and Alcohol fed series. The
main null hypothesis was As + Dw was not equal to As +
Ars Alb 30 or As + Ars Alb 200.
Results
ALT activity
Liver
The ALT activity in As-treated series was found to increase
at all intervals, as compared to that of Dw-controls (Fig 1).
There was a suppression of this increase from 72 hr
onwards in As + Ars Alb-30 group (p < 0.05), while the
increased enzyme activity appeared to be consistently sup-
pressed at all the fixation intervals in the As + Ars Alb-200
group (p < 0.01). However, when normal healthy
untreated mice were fed either Ars Alb-30 or Ars Alb-200
alone, the enzyme activity was apparently similar to that
of Dw-controls. Similarly, in normal healthy mice only
fed either A-30 or A-200 alone, there was no appreciable
increase or decrease of enzyme activity as compared to
that of Dw-fed controls. But interestingly enough, there
was no palpable suppression of increased enzymatic activ-
ity at most of the fixation times in either As + A-30 or As +
A-200 group (see Fig 1).
Blood
The ALT activity in blood of As-treated mice appeared to
increase at all the fixation intervals as compared to that of
Dw-controls except for 24 hr (Fig 2). In As + Ars Alb-30
group of mice, there was a clear suppression of this
increased enzyme activity (p < 0.01-0.001) at all the fixa-
tion times except for 24 h as compared to As-treated mice.
The same was true in As + Ars Alb-200 group (p < 0.01) at
all fixation intervals. In Ars Alb-30 or Ars Alb-200 group
of mice, there was no significant change in mean activities
of ALT in either liver or blood, as compared to that of Dw
control. However, conflicting results were obtained when
either A-30 or A-200 was fed to normal mice; while there
was an increase in enzymatic activity in blood of mice fed
A-30 at most fixation intervals (except for 7 day), there
was an appreciable increase (p < 0.01) of the enzyme
activity in mice fed A-200, as compared to that of Dw-fed
controls (p < 0.01-0.001, except at 15 d). Interestingly, on
the other hand, there was a rise in enzymatic activity in As
Showing ALT activities (µ/Mmg protein/min) in liver of different groups of mice at different time intervals Figure 1
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+ A-30 or As + A-200 group of mice at most fixation inter-
vals (except at 24 hr in case of As + A-200) as compared to
As-intoxicated mice, indicating stimulating/synergistic
effect of alcohol on As-intoxication (see Fig 2).
AST activity
Liver
The mean activities of AST were found to increase in AS-
treated group at all fixation intervals, as compared to that
of Dw-controls (Fig 3). The maximum increase was found
at 7d. In As +Ars Alb-30 or As + Ars Alb-200 mice, there
was a clear suppression of this increased enzyme activity
at most fixation times (p < 0.05-0.01) as compared to As-
treated mice. When normal healthy mice were either fed
Ars Alb-30 or Ars Alb-200 individually, there was no sig-
nificant change in their enzyme activity as compared to
that of Dw-controls. However, in As + A-30 or in As + A-
200 mice, there was an apparent increase in AST activity at
most fixation intervals (except at 24 hr and 30d) as com-
pared to As-treated mice. Again, in A-30 or A-200 group,
only a marginal increase in AST activity was observed (see
Fig 3) as compared to Dw-control.
Blood
The mean activities of AST were elevated in blood of As-
treated mice at all fixation intervals, as compared to that
of Dw-controls. In either As +Ars Alb-30 or As + Ars Alb-
200 group, there was a distinct suppression of this
increased AST activity at all fixation times (p < 0.01-
0.001). In Ars Alb-30 or Ars Alb-200 group, there was no
significant change in their enzymatic activity as compared
to either Dw-control. But the feeding of A-30 or A-200
alone to normal mice led to the increase in AST activity at
most fixation intervals, as compared to Dw-control. On
the other hand, a rise in enzymatic activity was observed
at most fixation intervals in As + A-30 or in As +A-200
group of mice as compared to As-treated mice (see Fig 4).
GSH level
Liver
The mean level of GSH was found to be decreased in the
As-treated series at all intervals of fixation, as compared to
that of Dw-controls. In As + Ars Alb-30 or As + Ars Alb-200
mice, there was clear evidence of prevention of this
decrease of GSH level at all fixation times, as compared to
Showing ALT activities (µ/Mmg protein/min) in blood of different groups of mice at different time intervals Figure 2
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that of the As-treated series (p < 0.05-0.01). On the other
hand, there was no significant change in the GSH level in
Ars Alb-30 or Ars Alb-200 group, as compared to that of
Dw-controls. However, there was a decrease in GSH level
in As + A-30 or As + A-200 at all intervals of fixation, like
that observed in As-treated mice. On the other hand, in A-
30 or A-200 mice, no significant change in GSH level
could be observed, as compared to that of Dw-controls
(see Fig 5).
Blood
The GSH level in blood of As-treated mice appeared to
decrease at all fixation intervals, as compared to that of
Dw-controls. In As + Ars Alb-30 or As + Ars Alb-200 group,
there was a spectacular prevention of decrease in GSH
level at all intervals of fixation (p < 0.05-0.001), as com-
pared to that of As-treated mice. In either Ars Alb-30 or Ars
Alb-200 mice, there was no visible change in their GSH
level, as compared to that of Dw-controls. In A-30 or A-
200 group, there was no appreciable change in GSH level
either with regard to Dw-control. On the other hand,
appreciable amount of decrease in GSH level was noted in
As + A-30 or As + A-200 group at most fixation times,
similar to what was encountered in As-treated series (see
Fig 6).
Discussion
In our earlier studies, liver appeared to be one of the
major organs in which arsenic caused considerable dam-
ages, tissue necrosis and other histological as well as bio-
chemical changes [10,11], [14,15]. Liver damage as a
consequence of arsenic poisoning has also been reported
in human subjects [21]. Determination of the enzymes
AST and ALT is the most common means of detecting liver
damage, the enzymes being raised several fold in the first
24 hr after damage [22]. However, there are a number of
other toxicity denoting compounds, of which reduced
glutathione (GSH) is one. This compound plays a protec-
tive role by detoxifying substances in one of the three
ways, namely, i) conjugation catalyzed by a glutathione
transferase, ii) chemical reaction with a reactive metabo-
lite to form a conjugate, or iii) donation of a proton or a
hydrogen ion to reactive metabolites or free radicals,
respectively [22].
Showing AST activities (µ/Mmg protein/min) in liver of different groups of mice at different time intervals Figure 3
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It has been suggested before [22] that reactive intermedi-
ates can react with GSH either by a direct chemical reac-
tion or by a glutathione transferase mediated reaction. If
excessive, these reactions can deplete the cellular glutath-
ione. Also, reactive metabolites can oxidize glutathione
and other thiol groups, such as those in proteins and
thereby cause a damage in thiol status. When the rate of
oxidation of glutathione exceeds the capacity of glutath-
ione reductase then oxidized glutathione (GSSG) is
actively transported out of the cell and thereby lost. The
reduced glutathione may be removed reversibly by oxida-
tion or formation of mixed disulfide or protein and irre-
versibly by conjugation or loss of the oxidized form from
the cell. Thus after exposure of cells to any compound
such as As2O3 which causes oxidative stress, glutathione
readily conjugates to reduce the cellular GSH level. There-
fore, the role of glutathione in cellular protection means
that if depleted of glutathione the cell is more vulnerable
to toxic compounds. Further, the modification of thiol
groups of enzymes, such as by As2O3 and other heavy met-
als, often leads to inhibition of this enzyme function, as
noted in the present study. Such enzyme also may have
critical endogenous roles such as regulation of ion con-
centration, active transport or mitochondrial metabolism.
There is evidence that alteration of protein thiols may also
be a crucial part of cell injury.
From the results of the present study, it was clearly dem-
onstrated that arsenic treatment induced toxicity in mice
as evidenced from the alterations in the enzymatic activi-
ties of AST and ALT and the reduced glutathione level in
both liver and blood. It was further shown that only
potentized Alcohol, i.e A-30 and A-200, tended to
enhance the toxicity induced by As-treatment while the
potentized drugs, Ars Alb-30 and Ars Alb-200 (potentized
in the alcohol "vehicle"), clearly showed protective
effects. Of these two potencies, Ars Alb-30 appeared to be
almost equally effective as that of Ars Alb-200 in bringing
about positive modulation of these enzymes, but the Ars
Alb-200 apparently had marginally better efficacy at 7d
and at subsequent longer fixation times. Incidentally,
intraperitoneal injection of serial dilutions of arsenic
compounds (arsenicus anhydride), mainly in decimal
potencies, have earlier been reported to increase arsenic
Showing AST activities (µ/Mmg protein/min) in blood of different groups of mice at different time intervals Figure 4
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elimination in varying amounts from blood of arsenic-
intoxicated rats through urine and faeces [17,23–25].
However, in our present study, another mammalian
model, mice have been used. We have not only used a dif-
ferent route of administration (oral) of the centesimally
potentized homeopathic drug, prepared from arsenic tri-
oxide, but we also dealt with a large number of parameters
and endpoints, starting from the actual deposition of
arsenic in different tissues, to genotoxic, to histological, to
enzymatic changes etc. in vivo at many more intervals
before fixation (10–11, 14–15), which helped us to
understand both early and relatively long-term effects of
the potentized homeopathic drug, Ars Alb-30 and Ars Alb-
200, which in every occasion most convincingly showed
an ameliorative (and persistently combating) effect
against arsenic poisoning as compared to the respective
controls. Recently, Rey [26] produced evidences that the
ultra-dilutions also contain initial properties of original
salts which can alter chemical and biological properties.
They demonstrated that despite their dilution beyond the
Avagadro number, the emitted light from ultra-dilutions
of lithium chloride and sodium chloride was specific of
the original salts dissolved initially. In the present study
also, the positive modulations in the levels of activities of
ALT and AST enzymes and reduced glutathione in the
potentized drug-fed mice could be clearly demonstrated
when the results of the As-treated series were compared
with the various control groups where the drugs were
either not administered to As-intoxicated mice, or admin-
istered to healthy As-untreated controls. It is quite amaz-
ing that such microdoses of a potentized homeopathic
drug, Arsenicum Album, which is produced by the dilu-
tion and succussion of the toxic substance (As2O3) itself,
were capable of bringing about such enzymatic alterations
in mice treated with a toxic dose of As2O3. Both Ars Alb-
30 and Ars Alb-200 apparently had the ability to detoxify
arsenic induced toxicity in both liver and blood. Inciden-
tally, the metabolic processes through which these
enzymes are formed and regulated, are strictly under con-
trol of certain genes, which are activated or deactivated at
certain physiological conditions of the cell. Therefore, any
sudden change in the genetic regulatory mechanism may
be a cause or a consequence of the entry of the toxic com-
pound, As2O3. As the potentized homeopathic drug, Ars
Showing GSH content (nM/mg) in liver of different groups of mice at different time intervals Figure 5
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Alb-30 or Ars Alb-200, is not expected to contain even a
single molecule of the original drug substance (As2O3), or
is expected to carry any other macromolecule, it is rather
difficult to explain the mechanism as to how these poten-
tized homeopathic drugs could render amelioration to the
As-toxicity. The pathway through which the potentized
homeopathic drugs execute their combating action can
also be hardly followed after it is administered on tongue
of the animal. Therefore, it becomes imperative that any
attempt to explain the mechanism of action of the home-
opathic drug would be highly speculative at the present
state of our knowledge. In one such effort, Khuda-Bukhsh
[27] advocated a hypothesis based on many circumstan-
tial scientific evidences and logic that one major pathway
of potentized homeopathic drugs could possibly be
through regulation of expression of certain relevant genes.
More and more evidences are being accumulated signify-
ing validity of this hypothesis [28–31]. Recently, Wiegant
and his collaborators [32–34] demonstrated the ability of
low concentration of a toxic chemical (sodium arsenite)
or "heat-shock" to produce "hormetic" effect in cells.
According to these authors, "hormetic effect" produced in
the cells exposed to the low dose, aroused certain protec-
tive activities that either reduced or helped in protection
or speedy recovery of the cells when they were exposed to
much stronger degree of such a stressful condition or to
toxic chemicals. They also showed that there were positive
changes in the m-RNA activities in generating molecular
chaperones like hsp proteins in response to artificially
induced stress conditions. Evidences of the presence of
some early response genes (ERG) which act in a fast and
transient manner in response to different physical, chem-
ical or environmental stresses, have also been on record
[32]. These genes become active whenever living system is
challenged with some kind of physical or chemical insult
or stress, in a bid to combat the stress-related damage,
either by activating or silencing the expression of some
other sets of genes. It is therefore quite probable that As-
intoxication deranges the activity of certain house-keep-
ing genes (e.g. the genes responsible for synthesizing
enzymes necessary for normal maintenance of cells and to
detoxify cellular environment, as and when necessary).
The ERG may also become active initially as a response to
protect the cellular environment. While these ERG can
Showing GSH content (nM/ml) in blood of different groups of mice at different time intervals Figure 6
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Table 1: Showing mean ± SE of AST and ALT activities and reduced glutathione content in blood and liver of different treatment groups 
of mice at different time intervals.
Time Intervals
Tissue Series 24 h 48 h 72 h 7 d 15 d 30 d
ALT activity (µM/mg protein/min)
Liver
Dw 0.244 ± 0.073 0.293 ± 0.034 0.318 ± 0.030 0.339 ± 0.085 0.328 ± 0.067 0.321 ± 0.065
As 0.280 ± 0.053 0.299 ± 0.048 0.344 ± 0.051 0.640 ± 0.024b 0.689 ± 0.065b 0.643 ± 0.063b
As+Ars Alb-30 0.328 ± 0.077 0.217 ± 0.044 0.319 ± 0.084 0.466 ± 0.039b 0.473 ± 0.067a 0.322 ± 0.080a
As+Ars Alb-200 0.257 ± 0.093 0.264 ± 0.044 0.327 ± 0.068 0.518 ± 0.062 0.306 ± 0.056b 0.277 ± 0.050a
As+A-30 0.653 ± 0.113 0.318 ± 0.060 0.399 ± 0.042 0.599 ± 0.109b 0.644 ± 0.100 0.650 ± 0.091
As+A-200 0.511 ± 0.079 0.345 ± 0.045 0.396 ± 0.064 0.610 ± 0.078 0.660 ± 0.074 0.767 ± 0.096
Blood Dw 0.715 ± 0.032 0.740 ± 0.093 0.987 ± 0.081 0.766 ± 0.062 0.639 ± 0.034 0.736 ± 0.066
As 0.651 ± 0.097 0.910 ± 0.065 1.311 ± 0.109a 1.004 ± 0.076a 0.950 ± 0.079b 1.003 ± 0.059a
As+Ars Alb-30 0.741 ± 0.069 0.630 ± 0.019 0.852 ± 0.094a 0.878 ± 0.088 0.307 ± 0.044c 0.273 ± 0.044c
As+Ars Alb-200 0.538 ± 0.066 0.521 ± 0.050 1.049 ± 0.093 0.875 ± 0.070 0.571 ± 0.082a 0.409 ± 0.061c
As+A-30 1.209 ± 0.133 0.938 ± 0.098 1.617 ± 0.097 0.939 ± 0.063b 1.253 ± 0.106 0.902 ± 0.063
As+A-200 0.564 ± 0.034 1.002 ± 0.103 1.522 ± 0.097 0.928 ± 0.107 1.106 ± 0.194 1.212 ± 0.121
AST activity (µM/mg protein/min)
Liver
Dw 0.288 ± 0.038 0.214 ± 0.033 0.233 ± 0.042 0.259 ± 0.039 0.272 ± 0.016 0.257 ± 0.018
As 0.289 ± 0.024 0.282 ± 0.026 0.236 ± 0.018 0.433 ± 0.043a 0.341 ± 0.024a 0.319 ± 0.019a
As+Ars Alb-30 0.241 ± 0.023 0.224 ± 0.037 0.215 ± 0.022 0.222 ± 0.018b 0.308 ± 0.045 0.216 ± 0.044
As+Ars Alb-200 0.250 ± 0.043 0.278 ± 0.046 0.213 ± 0.037 0.241 ± 0.011b 0.194 ± 0.031b 0.088 ± 0.009c
As+A-30 0.255 ± 0.037 0.301 ± 0.033 0.276 ± 0.045 0.327 ± 0.023a 0.372 ± 0.047a 0.239 ± 0.058
As+A-200 0.333 ± 0.062 0.285 ± 0.026 0.243 ± 0.034 0.363 ± 0.041 0.339 ± 0.040 0.298 ± 0.036
Blood
Dw 0.199 ± 0.023 0.221 ± 0.016 0.241 ± 0.014 0.239 ± 0.016 0.243 ± 0.016 0.243 ± 0.009
As 0.309 ± 0.018b 0.282 ± 0.020a 0.424 ± 0.021c 0.294 ± 0.013a 0.530 ± 0.053c 0.383 ± 0.018c
As+Ars Alb-30 0.247 ± 0.025 0.204 ± 0.015a 0.204 ± 0.004c 0.194 ± 0.026b 0.304 ± 0.029b 0.287 ± 0.026a
As+Ars Alb-200 0.263 ± 0.015 0.210 ± 0.009a 0.249 ± 0.020c 0.200 ± 0.015a 0.268 ± 0.027b 0.229 ± 0.018c
As+A-30 0.385 ± 0.026a 0.311 ± 0.041 0.426 ± 0.037 0.387 ± 0.031 0.549 ± 0.047 0.498 ± 0.036a
As+A-200 0.389 ± 0.021a 0.319 ± 0.028 0.478 ± 0.041 0.293 ± 0.031 0.542 ± 0.061 0.460 ± 0.033
GSH Content (µM/mg of Liver)
Liver
Dw 1.383 ± 0.064 1.240 ± 0.051 1.162 ± 0.072 1.359 ± 0.072 1.376 ± 0.111 1.238 ± 0.110
As 1.447 ± 0.066 1.061 ± 0.035a 0.978 ± 0.073 0.757 ± 0.033c 0.782 ± 0.092b 0.615 ± 0.098b
As+Ars Alb-30 1.483 ± 0.086 1.377 ± 0.065b 1.344 ± 0.066b 1.207 ± 0.122b 1.196 ± 0.109a 1.055 ± 0.045b
As+Ars Alb-200 1.580 ± 0.105 1.145 ± 0.084 1.230 ± 0.093 1.173 ± 0.108b 1.265 ± 0.084b 1.187 ± 0.077b
As+A-30 1.360 ± 0.119 0.817 ± 0.082a 0.818 ± 0.048 0.832 ± 0.115b 0.697 ± 0.116 0.474 ± 0.045
As+A-200 1.436 ± 0.109 0.924 ± 0.117 0.937 ± 0.100 0.758 ± 0.074 0.718 ± 0.091 0.692 ± 0.035
GSH Content (nM/ml of Blood)
Blood
Dw 296.779 ± 6.948 274.076 ± 9.037 284.093 ± 6.839 275.882 ± 8.284 274.503 ± 7.090 241.913 ±
12.136
As 275.882 ±
11.433
245.502 ±
7.214a
265.208 ±
11.621
237.456 ±
7.442b
142.375 ±
16.466c
110.200 ± 7.47c
As+Ars Alb-30 303.881 ± 9.855 300.925 ±
14.232b
286.556 ±
16.079
236.388 ±
15.958
284.011 ±
18.742c
182.191 ±
14.149c
As+Ars Alb-200 281.630 ±
11.363
226.324 ±
13.620
274.651 ±
14.291
299.037 ±
17.341a
313.898 ±
12.932c
286.967 ±
7.691b
As+A-30 240.248 ±
17.659
236.635 ± 3.915 235.239 ±
10.893
102.569 ±
6.585b
104.811 ± 6.347 87.281 ± 9.834
As+A-200 259.953 ± 8.857 274.856 ±
14.680
181.869 ±
12.780c
153.213 ±
17.617b
146.809 ±
13.915
106.740 ± 6.259
Superscript on the value of As series show level of significance in t-test between Dw and As and that on other series show the level of significance 
of t-test between As and that series. a = p < 0.05, b = p < 0.01, c = p < 0.001BMC Complementary and Alternative Medicine 2003, 3 http://www.biomedcentral.com/1472-6882/3/7
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protect cells from damage caused by low concentration of
toxic substances (up to a certain limit) and eventually suc-
ceed in developing greater capabilities within cells to
tackle subsequent "shock" or "insult" by greater dose of
the toxic substance, they eventually fail if and when the
dose or level of toxicity goes beyond the threshold limit.
The administration of Alcohol-30 or Alcohol-200 (the
blank "vehicle") was unable to restore the damage
induced by As-intoxication. On the other hand, the suc-
cess of the potentized homeopathic drug towards restora-
tion of normalcy to a considerable extent in levels of
enzyme activity and reduced glutathione level after As-
toxicity would indicate that the drug could somehow be
able to effectively modify or correct the gene functioning
related to the synthesis and release of these enzymes and
compounds with an ameliorative effect in correct propor-
tions, which the succussed alcohol without medicinal
property failed to do. Therefore, the potentized drugs con-
tained in them definite signals which were apparently
missing in the succussed alcohol. Indeed, a considerable
amount of data so far accumulated tend to show that
homeopathic drugs do have abilities to bring in noticea-
ble protective changes at certain physiological and cytoge-
netical levels, which are known to be strictly under genetic
control [27,29–31]. As for example, the homeopathic
drugs have been shown to be capable of repairing DNA
damage or chromosome damage induced by X-irradia-
tions [35–37], or by chemical mutagens [38] or by ultra-
sonic sound waves [28]. Incidentally, the entire
mechanism of repair of DNA in such cases is known to be
controlled by certain genes (e.g. genes like uvr A, uvr B and
uvr C having exonuclease activity and also XPA,.XPB, XPC,
XPD genes etc. in mice having direct repair action through
damage recognition and DNA binding). Therefore, there
must be some definite link between the homeopathic
drug and the responsible genes at some level. The same
conclusion is arrived at when potentized homeopathic
drug clearly shows ameliorative effects on the incidence of
p-DAB induced liver tumors [29,30], which must involve
a restrictive mechanism on the conversion of the proto-
oncogenes to oncogenes for effective tumorigenesis.
Therefore, in the absence of any original drug molecule,
all that these potentized homeopathic drugs can really do
is to emit certain corrective signals which, when perceived
by relevant receptors [39], can either activate or deactivate
certain genes. They must get the required work done
through the help of mechanisms that must be already
operative in the living organisms, either by accelerating or
by inhibiting certain intrinsic systems in operation. Thus,
signal transduction pathway(s) and different steps at
which eukaryotic genes are known to be regulated, say, at
the trancriptional, translational level, or post-tranlational
level, etc. are some areas of future research that can prove
to be rewarding in understanding the molecular mecha-
nism(s) of the potentized homeopathic drugs. Inciden-
tally, the evidence that potentized homeopathic drug
failed to elicit the desired effect when Actinomycin D, a
transcription blocker, was simultaneously fed, also speaks
in favor of the fact that homeopathic drugs need transcrip-
tion process to go on for effective functioning [13,28].
Recently, the gene products of p53 (a tumor-suppressor
gene) and Bcl2 (an apoptotic gene) have been measured
through immuno-blot (Western) experiments in two
groups of mice undergoing carcinogenesis, one regularly
fed a potentized homeopathic drug, and the other not fed
with the drug (Khuda-Bukhsh, Biswas et al., unpublished
data). There was clear evidence from the initial study that
the homeopathic drug indeed positively influenced the
expressions of these two individual genes in the mice
undergoing the process of carcinogenesis; the repeat
experiments are presently underway. But whether or not
the molecular mechanism of action of the microdoses is
precisely understood at the moment, the positive aspects
of the drug, Ars Alb, that make its use less hazardous, are:
i) its efficacy in micro doses, and ii) no adverse side-effects
or toxic effects of its own when fed to normal controls.
Conclusion
As supplying arsenic-free drinking water can not totally
rule out chances of arsenic contamination from other
sources, the problem of eradicating arsenic related dis-
eases can not be addressed through such effort alone. The
results of our earlier and present studies convincingly
demonstrate that the potentized homeopathic drug,
Arsenicum Album, not only has the ability to help
removal of arsenic from the body, but these drugs in
microdoses appear to have the ability to detoxify the ill-
effects produced by arsenic in mice, a mammal which has
close functional semblance to that of human beings.
Therefore, the present findings would further add support
to our earlier contention that the potentized homeopathic
drugs could be strong candidates for effective use in alle-
viating arsenic-related diseases in the contaminated areas,
at least till better facilities can be made available to the
risk-exposed people to combat this problem more effec-
tively by some other tested means. Therefore, conducting
a pilot clinical trial to ascertain the extent of efficacy, if
any, of this potentized homeopathic drug on human vol-
unteers inhabiting arsenic-risk areas of West Bengal
(under the joint supervision of scientists and qualified
medical practitioners) in combating arsenic poisoning
seems to be a relevant proposition worth a serious
consideration.
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